Who we are
As a leading global clinical-stage biopharmaceutical company, we strive to create transformative medicines to protect and improve people’s lives. Fueled by our proprietary RNA technology platform combined with two decades of science and manufacturing excellence, we are dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
Newsflash
CureVac N.V. (Nasdaq: CVAC) – (May 6, 2022) Major shareholder dievini Hopp BioTech holding GmbH & Co. KG, DH-LT-Investments GmbH and Dietmar Hopp, along with the managing directors of dievini and associated entities, have executed a private transaction in which they have transferred shares of CureVac’s stock among themselves. This transaction follows an announcement on February 22, 2022, where the parties disclosed that they no longer wish to sell part of their shareholding in CureVac, save for private transfers amongst themselves. The shares were transferred as part of an implementation plan to transfer the ownership of dievini Hopp BioTech holding entirely into the hands of the family of Dietmar Hopp and a family foundation. Following the completion of the transaction, dievini and related entities now own 86,160,390 shares in the company, or approximately 46%. Dietmar Hopp initially invested in CureVac in 2005 and has remained a strong supporter of the Company and the future of its mRNA technology.
The transaction was disclosed in a filing with the Securities & Exchange Commission made on May 5, 2022, which is available here. Large shareholders that own at least 5% of a CureVac stock are required to disclose their sales and purchases with the SEC.
